

FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY



SUPPORT THAT GETS YOU GOING AND **KEEPS YOU GOING**

**DETERMINE YOUR MOST CONVENIENT AND AFFORDABLE PATH
TO STARTING TREATMENT WITH ILUMYA®**

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

SELECTED IMPORTANT SAFETY INFORMATION

ILUMYA is not for everyone, only your doctor can determine if it's right for you. Do not take ILUMYA if you are allergic to ILUMYA or any of its ingredients. ILUMYA may lower your ability to fight infections and may increase your risk of infections. Before starting treatment, your doctor should check you for tuberculosis and infections.

**Please read the Important Safety Information on
pages 6 and 7 of this brochure and the enclosed full
Prescribing Information and Medication Guide.**

Visit [ILUMYA.com](https://www.ilumya.com) for more information.

 **ILUMYA®**
tildrakizumab-asmn
Injection 100 mg/mL

Affordable treatment options for any level of coverage

COMMERCIAL INSURANCE

ILUMYA® EARLY ACCESS PROGRAM

If you have commercial insurance, you will be automatically enrolled in this program and are eligible to receive ILUMYA® (tildrakizumab-asmn) for free for up to 2 years.*



ILUMYA® COPAY PROGRAM

With the ILUMYA® Copay Card, eligible patients with commercial insurance may pay no more than \$0 per dose.†

Sign up for our ILUMYA® copay card at:
www.ilumya.com/help-from-our-team/#copay-card

*Eligibility rules apply. Patients must be commercially insured. For patients to remain eligible for the Early Access Program, providers must submit a medical and/or pharmacy prior authorization form before a patient's third dose. See full terms and conditions at ILUMYA.com/savings.

†Subject to terms and conditions. Must be enrolled in ILUMYA SUPPORT® to qualify. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state- or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE. Income documentation required. Available to US, Guam, Virgin Islands, or Puerto Rico residents only. See the full terms and conditions for ILUMYA SUPPORT® programs at ILUMYA.com/savings.

Pay as little as \$0 for ILUMYA® under Medicare Part B‡

MEDICARE PART B

Because ILUMYA® (tildrakizumab-asmn) can only be administered by a medical professional, treatment is covered under Medicare Part B as a medical benefit. This means eligible patients with Medicare Part B and supplemental insurance may pay as little as \$0 for each dose of ILUMYA®.

What is a medical benefit?

Medicare Part B helps pay for services provided by doctors, dermatologists, and other healthcare professionals as a medical benefit. It also covers outpatient services needed to administer prescriptions—like infusions or injections.



NO INSURANCE OR UNDERINSURED

PATIENT ASSISTANCE PROGRAM

If you do not have enough insurance coverage or do not have insurance at all, you may be eligible to receive ILUMYA® at no cost through the Patient Assistance Program. Your doctor can help enroll you within this program. Documentation of your income will be required, so keep that handy if you'd like to discuss this option at your next appointment.

‡Medicare Part B coverage has a 20% cost share for ILUMYA®, but with supplemental insurance, your prescription may be covered in full.


Get started with ILUMYA SUPPORT Lighting the Way®



ASK

Ask your doctor to submit your ILUMYA SUPPORT Lighting the Way® enrollment form. You can also access your enrollment form by texting **ACTIVATE** to **20808** or complete it online at [ILUMYA.com/activate](https://www.ilumya.com/activate).

It's important to submit your ILUMYA SUPPORT® enrollment form to receive all the benefits available to you.




Once you are enrolled in ILUMYA SUPPORT®, you will be eligible for personalized support emails, text message reminders, coverage information, and savings offered through this valuable support program.



CONFIRM

We will confirm your coverage options with ILUMYA® (tildrakizumab-asmn). Your enrollment in ILUMYA SUPPORT Lighting the Way® allows us to check with your insurance company to make sure you are qualified for ILUMYA® coverage and find out if you are eligible for our financial support programs.



PREPARE

Be prepared for a call from your ILUMYA SUPPORT® team (**855-445-8692**) or your specialty pharmacy (SP) to receive your coverage benefits. They will let you know when your prescription will be delivered to your doctor's office. Knowing this will help you to schedule your first treatment appointment.

Once your prescription has been processed by ILUMYA SUPPORT® or the SP, they will send your ILUMYA® (tildrakizumab-asmn) treatment to your doctor's office.

Make sure to get the SP's phone number so you can prepare for all your future treatments with ILUMYA®.



SCHEDULE

Schedule an appointment with your doctor for your first dose of ILUMYA®. With personalized support from ILUMYA SUPPORT Lighting the Way®, scheduling your treatment appointments couldn't be easier.

What determines where I receive treatment?

You will receive your injection by a healthcare provider at either your physician's office or an alternate location that provides similar healthcare services, and may be more convenient to you. If a different site offers more convenient hours or location, the ILUMYA SUPPORT® team will work with your physician to verify the alternative center of care. If you do receive treatment off-site, you will still have regular appointments with your healthcare provider to check in on the progress of your treatment.



What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)



get lost!
had to make a stop to
ask for directions

best meal in
days!

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “**What is the most important information I should know about ILUMYA?**”
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?


ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include: upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full Prescribing Information and Medication Guide for ILUMYA and discuss any questions with your doctor.

 **ILUMYA®**
tildrakizumab-asmn
Injection 100 mg/mL



ILUMYA SUPPORT

L I G H T I N G T H E W A Y ®

3 ways to activate your account

Enroll through your healthcare provider to receive the coverage and savings benefits available to you, or activate your account now to start your membership.



TEXT **ACTIVATE**
TO **20808**



VISIT
ILUMYA.COM/
ACTIVATE



CALL **855-4ILUMYA**
(855-445-8692)



By activating, you agree to receive marketing and other loyalty program text messages and emails, including messages sent using an autodialer. You understand that consent is not required as a condition of purchase.



**Patient support for
the long haul**

 **ILUMYA**®
tildrakizumab-asmn
Injection 100 mg/mL



The ILUMYA registered trademarks are the property of Sun Pharmaceutical Industries Limited.
© 2022 Sun Pharmaceutical Industries, Inc. All rights reserved.
PM-US-ILY-2086 10/2022